Dr. Muneeba Ahsan Sayeed

Name

Dr. Muneeba Ahsan Sayeed

Designation

Assistant Professor / Head of Department

Email

muneeba.ahsan@duhs.edu.pk

Office

Admin Block, Sindh infectious diseases hospital and research centre, Gulshan e Iqbal block 10, near chase up, NIPA, Karachi

Qualifications

  • MBBS
  • FCPS (Medicine)
  • FCPS (ID)
  • FACP

Research

  1. Case report: HYPOTHYROIDISM SIMULATING POLYMYOSITIS Published in Pakistan Medical Association (JPMA) ). J Pak Med Assoc. 2015 May;65(5):559-60. PMID: 26028394
  2. Case report: HYPERMUCOVISCOUS KLEBSIELLA SYNDROME published in Journal of Pakistan Medical Association (JPMA). J Pak Med Assoc. 2017 Dec;67(12):1930-1932.
  3. Case series: RALSTONIA PICKETTII BACTEREMIA: AN EMERGING INFECTION IN A TERTIARY CARE HOSPITAL SETTING. Cureus 11(7):e5084. DOI 10.7759/cureus.5084.
  4. XPOSURE OF HEALTH CARE WORKERS TO HOSPITALIZED CRIMEAN-CONGO HEMORRHAGIC FEVER CASES AND THEIR MANAGEMENT, Infectious Diseases Journal Pakistan Vol 27, Issue Jan-March 2018
  5. CLINICAL SPECTRUM AND FACTORS IMPACTING OUTCOME OF CANDIDA AURIS: A SINGLE CENTER STUDY FROM PAKISTAN, BMC Infect Dis.2019 May 6;19(1):384. doi: 10.1186/s12879-019-3999-y.
  6. COMPARISON OF RISK FACTORS AND OUTCOME OF CANDIDA AURIS CANDIDEMIAWITH NON-CANDIDA AURIS CANDIDEMIA: A RETROSPECTIVE STUDY FROM PAKISTAN. Med Mycol. 2019 Nov 27. doi: 10.1093/mmy/myz112.
  7. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH SEVERE COVID-19 PNEUMONIA AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN. Cureus 13(2):e13107. doi:10.7759/cureus.13107
  8. HYPERIMMUNE ANTI-COVID-19 IVIG (C-IVIG) TREATMENT IN SEVERE AND CRITICAL COVID-19 PATIENTS: A PHASE I/II RANDOMIZED CONTROL TRIAL. EClinicalMedicine, Volume 36, 2021,100926,ISSN 2589-5370,
    https://doi.org/10.1016/j.eclinm.2021.100926
  9. VENTILATOR ASSOCIATED PNEUMONIA IN TRAUMA PATIENTS; ASSOCIATED RISK FACTORS, MICROBIAL ETIOLOGY AND OUTCOME. Pak Armed Forces Med journal Vol 71 No 4 (2021): August. DOI:
    https://doi.org/10.51253/pafmj.v71i4.6278
  10. EFFICACY OF HETEROLOGOUS BOOSTING AGAINST SAR-COV-2 USING A RECOMBINANT INTERFERON-ARMED FUSION PROTEIN VACCINE (V-01): A RANDOMIZED, DOUBLE-BLIND AND PLACEBO-CONTROLLED PHASE III TRIAL. Emerging Microbes & Infections, Volume 11,2022 11:1, 1910-1919, DOI: 10.1080/22221751.2022.2088406
  11. DESIGN AND IMMUNOINFORMATIC ASSESSMENT OF CANDIDATE MULTIVARIANT mRNA VACCINE CONSTRUCT AGAINST IMMUNE ESCAPE VARIANTS OF SARS-COV2. August 2022 Polymers 14(16), DOI: 10.3390/polym14163263
  12. PHASE II/III TRIAL OF HYPERIMMUNE ANTI-COVID-19 INTRAVENOUS IMMUNOGLOBULIN (C-IVIG)THERAPY IN SEVERE COVID-19 PATIENTS: study protocol for a randomized controlled trial. Trials 23, 932 (2022).
    https://doi.org/10.1186/s13063-022-06860-2.
  13. FREQUENCY OF RAISED CARDIAC BIOMARKERS IN PATIENTS WITH COVID-19 INFECTION AND ITS ASSOCIATION WITH MORTALITY (idj.org.pk). http://ojs.idj.org.pk/index.php/Files/article/view/103/145
  14. EFFICACY OF HETEROLOGOUS BOOSTING AGAINST SARS-COV-2 USING A RECOMBINANT INTERFERON-ARMED FUSION PROTEIN VACCINE (V-01): A randomized, double-blind and placebo-controlled phase III trial. Emerg Microbes Infect. 2022 Dec;11(1):1910-1919. doi: 10.1080/22221751.2022.2088406.
    https://pubmed.ncbi.nlm.nih.gov/35686572/
  15. CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF COVID-19 PATIENTS DURING THE DELTA-OMICRON WAVE WITH RISK ASSESSMENT OF ADVERSE OUTCOMES. J Coll Physicians Surg Pak. 2023 Mar;33(3):297-302. doi: 10.29271/jcpsp.2023.03.297
  16. COMPARISON OF CLINICAL DISEASE SEVERITY AND OUTCOME OF VACCINATED COVID-19 PATIENTS WITH UNVACCINATED PATIENTS IN A SPECIALIZED COVID-19 FACILITY: A Retrospective Cohort Study from Karachi, Pakistan. Vaccines 2023, 11,1178.
    https://doi.org/10.3390/vaccines11071178.